• Our Company

QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

For more information please visit www.quintilesims.com.

Driving Healthcare Performance in Croatia

QuintilesIMS has been monitoring the Croatian pharmaceutical market since 1997 and established a local presence in Zagreb in 2001. QuintilesIMS Croatia has a comprehensive offering portfolio adjusted to local market needs; its solutions for the pharmaceutical industry based on wholesaler market data and full range of consulting services help clients to optimize their commercial effectiveness and improve business performance.

In 2011, QuintilesIMS Croatia made advanced analytics available through IMS Market Viewer, offering customers an improved and faster level of analytics and allowing them to derive maximum business value from our databases. The following year, an additional investment was made with the launch of our Over-The-Counter analytics offering. This new database with significantly enlarged product coverage has helped clients to monitor the growing segment of consumer health products.

During the last decade, QuintilesIMS Croatia has witnessed the changes and development of the local market and played a leading role in supporting local clients to interpret and analyze trends and opportunities, and improve performance.

In 2012, the size of the ethical pharmaceutical market in Croatia (retail and hospital) reached €684 million, representing a small decrease (-0.3%) from 2011. The key therapeutic area is Cardiovascular, followed by Oncology with a growth of more than 5% from 2011.